title: Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
abstract: In autosomal dominant polycystic kidney disease (ADPKD), aberrant proliferation of the renal epithelial cells is responsible for the formation of numerable fluid-filled cysts, massively enlarged kidneys, and progressive loss of renal function. cAMP agonists, including arginine vasopressin, accelerate cyst epithelial cell proliferation through protein kinase A activation of the B-Raf/MEK/extracellular signal-regulated kinase (ERK) signaling pathway. The mitogenic effect of cAMP is equally potent and additive to growth factor stimulation. Here, we determined whether Sorafenib (BAY 43-9006), a small molecule Raf inhibitor, inhibits proliferation of cells derived from the cysts of human ADPKD kidneys. We found that nanomolar concentrations of Sorafenib reduced the basal activity of ERK, inhibited cAMP-dependent activation of B-Raf and MEK/ERK signaling, and caused a concentration-dependent inhibition of cell proliferation induced by cAMP, epidermal growth factor, or the combination of the two agonists. Sorafenib completely blocked in vitro cyst growth of human ADPKD cystic cells cultured within a three-dimensional collagen gel. These data demonstrate that cAMP-dependent proliferation of human ADPKD cyst epithelial cells is blocked by Sorafenib and suggest that small molecule B-Raf inhibitors may be a therapeutic option to reduce the mitogenic effects of cAMP on cyst expansion.
authors.forename: Tamio
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Gail A
authors.initials: GA
authors.lastname: Reif
authors.forename: James P
authors.initials: JP
authors.lastname: Calvet
authors.forename: Darren P
authors.initials: DP
authors.lastname: Wallace
mesh_terms: D001557:Benzenesulfonates / Q000627:therapeutic use*; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D004815:Epidermal Growth Factor / Q000494:pharmacology; D004847:Epithelial Cells / Q000187:drug effects* / Q000201:enzymology*; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D016891:Polycystic Kidney, Autosomal Dominant / Q000201:enzymology* / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000378:metabolism; D019908:Proto-Oncogene Proteins c-raf / Q000378:metabolism; D011725:Pyridines / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D000077157:Sorafenib
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D004815:Epidermal Growth Factor; D000077157:Sorafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D019908:Proto-Oncogene Proteins c-raf; D017868:Cyclic AMP-Dependent Protein Kinases; D020928:Mitogen-Activated Protein Kinases
references.citation: Lancet. 2007 Apr 14;369(9569):1287-1301
references.pmid: 17434405
references.citation: Cell Tissue Res. 2006 Dec;326(3):671-85
references.pmid: 16767405
references.citation: Nephron Exp Nephrol. 2004;98(1):e1-7
references.pmid: 15361692
references.citation: J Lab Clin Med. 1996 Feb;127(2):214-22
references.pmid: 8636651
references.citation: J Biol Chem. 2004 Sep 24;279(39):40419-30
references.pmid: 15263001
references.citation: Kidney Int. 2004 Sep;66(3):964-73
references.pmid: 15327388
references.citation: Nat Med. 2003 Oct;9(10):1323-6
references.pmid: 14502283
references.citation: J Biol Chem. 2009 Mar 13;284(11):7214-22
references.pmid: 19098310
references.citation: Mol Cell Biol. 2009 May;29(9):2359-71
references.pmid: 19255143
references.citation: Oncogene. 2008 Feb 7;27(7):877-95
references.pmid: 17724477
references.citation: Semin Nephrol. 2001 Mar;21(2):107-23
references.pmid: 11245774
references.citation: Cell. 2005 Apr 22;121(2):179-93
references.pmid: 15851026
references.citation: Clin J Am Soc Nephrol. 2010 Jul;5(7):1312-29
references.pmid: 20498248
references.citation: Nat Rev Drug Discov. 2006 Oct;5(10):835-44
references.pmid: 17016424
references.citation: J Biol Chem. 2000 Sep 1;275(35):27354-9
references.pmid: 10869359
references.citation: Kidney Int. 2003 Feb;63(2):427-37
references.pmid: 12631108
references.citation: J Am Soc Nephrol. 2006 Aug;17(8):2220-7
references.pmid: 16807403
references.citation: J Am Soc Nephrol. 2006 Jan;17(1):178-87
references.pmid: 16319189
references.citation: Kidney Int. 2007 Jul;72(2):157-65
references.pmid: 17396115
references.citation: Kidney Int. 2005 Jul;68(1):206-16
references.pmid: 15954910
references.citation: Kidney Int. 2008 Feb;73(3):269-77
references.pmid: 17943077
references.citation: J Am Soc Nephrol. 2006 Oct;17(10):2821-31
references.pmid: 16928806
references.citation: Kidney Int. 2000 Apr;57(4):1460-71
references.pmid: 10760082
references.citation: Oncogene. 2004 Aug 19;23(37):6292-8
references.pmid: 15208680
references.citation: Kidney Int Suppl. 1997 Dec;63:S93-7
references.pmid: 9407432
references.citation: Nature. 2002 Jun 27;417(6892):949-54
references.pmid: 12068308
references.citation: Trans Assoc Am Physicians. 1990;103:48-52
references.pmid: 1966746
references.citation: J Am Soc Nephrol. 2002 Sep;13(9):2384-98
references.pmid: 12191984
references.citation: Kidney Int. 1996 Oct;50(4):1327-36
references.pmid: 8887295
references.citation: J Am Soc Nephrol. 2008 Jan;19(1):102-8
references.pmid: 18032793
references.citation: Clin Cancer Res. 2006 Mar 1;12(5):1623-9
references.pmid: 16533790
references.citation: Nat Med. 2004 Apr;10(4):363-4
references.pmid: 14991049
references.citation: Clin J Am Soc Nephrol. 2009 Jun;4(6):1140-50
references.pmid: 19443627
references.citation: Kidney Int. 2003 Jun;63(6):1983-94
references.pmid: 12753285
references.citation: J Am Soc Nephrol. 2000 Jul;11(7):1179-1187
references.pmid: 10864573
references.citation: EMBO J. 1999 Apr 15;18(8):2137-48
references.pmid: 10205168
references.citation: J Am Soc Nephrol. 2006 Jun;17(6):1604-14
references.pmid: 16641154
references.citation: Trends Cell Biol. 2002 Jun;12(6):258-66
references.pmid: 12074885
references.citation: J Am Soc Nephrol. 2006 Jun;17(6):1498-500
references.pmid: 16687624
references.citation: Am J Physiol Renal Physiol. 2008 Nov;295(5):F1463-71
references.pmid: 18753297
references.citation: J Am Soc Nephrol. 2005 Apr;16(4):846-51
references.pmid: 15728778
references.citation: Cancer Res. 2004 Oct 1;64(19):7099-109
references.pmid: 15466206
references.citation: Physiol Rev. 1998 Oct;78(4):1165-91
references.pmid: 9790573
references.citation: Curr Opin Pharmacol. 2005 Aug;5(4):350-6
references.pmid: 15955734
references.citation: Semin Nephrol. 1999 Jul;19(4):327-43
references.pmid: 10435671